CCR News: Clinical Trials

Stem cell transplant process

Clinical trial tests new methods for blood stem cell transplant in lymphoma

Jun 6, 2019

Peripheral T-cell lymphoma (PTCL) is a rare, often fast-growing cancer of white blood cells. A new clinical trial is investigating to see how a new approach to blood stem cell transplant can impact patients with PTCL.  Read more...

Head and neck cancer regions

Investigators test combination therapy for head and neck squamous cell carcinoma in new trial

Jun 4, 2019

Patients with recurrent head and neck squamous cell carcinoma (HNSCC) may be eligible to participate in a new clinical trial at the NIH Clinical Center. This trial tests a therapy of a novel radiosensitizer, birinapant, in combination with radiotherapy for patients whose HNSCC has come back at or near the place of the original tumor. Read more...

Drawing of inside of brain

Clinical trial tests a new drug therapy for recurrent ependymomas of the brain and spinal cord

May 28, 2019

Ependymomas are rare tumors that arise in the ependyma, the thin membrane that lines fluid-filled cavities in the brain and spinal cord, and there are limited treatment options for those that have already been treated with standard therapies. A new clinical trial is testing a drug that targets ependymomas that have a specific genetic signature. Read more...

Doctor with patient

Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer

May 16, 2019

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC. Read more...

hepatocellular carcinoma

Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer

May 14, 2019

A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases. 

  Read more...

histological slide of prostate cancer

New clinical trial tests radiotracer for improved imaging of metastatic prostate cancer

Apr 22, 2019

Most forms of prostate cancer have receptors for prostate-specific membrane antigen (PSMA), a protein that helps fuel the development of prostate cancer cells. Investigators are studying if a radiotracer that binds to PSMA may improve imaging methods to find sites of metastatic prostate cancer. Read more...

Anatomy of female urinary system

Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects

Apr 18, 2019

Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA. Read more...

Hernandez clinical trial conversation

New study delivers chemotherapy to the liver for metastatic colorectal cancer patients

Apr 3, 2019

In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read more...

Patient-derived glioma stem cells

New clinical trial will determine if gliomas respond to immunotherapy

Apr 1, 2019

Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.  Read more...

Micrograph of a diffuse large B cell lymphoma

Trial results show that younger lymphoma patients respond well to ibrutinib

Mar 26, 2019

A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older. Read more...

Pages